trending Market Intelligence /marketintelligence/en/news-insights/trending/rrxvpdyigeilyw9g6orqvg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Progenics' Azedra therapy wins US FDA approval to treat 2 rare tumors

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Progenics' Azedra therapy wins US FDA approval to treat 2 rare tumors

Progenics Pharmaceuticals Inc., a New York-based developer of cancer treatments, won U.S. Food and Drug Administration approval for Azedra, a treatment for two uncommon types of tumors.

Azedra may be used for certain patients age 12 and older who have either pheochromocytoma or paraganglioma that cannot be surgically removed, have spread beyond the original tumor site and require systemic anti-cancer therapy.

Pheochromocytoma is usually a benign tumor that develops in an adrenal gland, according to the Mayo Clinic. Adrenal glands sit on top of the kidneys and produce sex and stress hormones.

In pheochromocytoma, the tumor releases hormones that can lead to high blood pressure, which can result in damage to the cardiovascular system and other tissues if left untreated. Most people who develop the condition are between 20 and 50.

Paraganglioma originates in nerve cells found throughout the body. The tumor grows slowly, although it can become malignant and invasive. About half of these paraganglioma tumors can produce hormones that can induce high blood pressure, a rapid heartbeat, flushes, sweating, headache or tremors. Current treatment options include surgery and radiation therapy.